by Raynovich Rod | May 18, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, vaccines
Race to Develop a Coronavirus Vaccine Has $BB Funding with Several Major Players Update-3 5/20…Reversal to upside from yesterday’s sell-off. However the cynics are starting to come out questioning the timelines of some of the major COVID vaccine players...
by Raynovich Rod | Apr 30, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, vaccines
5/11/20 330p EDT Crazy market running up again in healthcare, life sciences and biotech; cyclicals continue to lag. XBI break-out to new highs at $104 up 4.7%. IBB up 3.94% to $133. This run reminds me of JY 2015 last big blowoff and speculative frenzy. But small...
by Raynovich Rod | Apr 26, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 4/29 12:15p Mid-day trading -Healthcare weak as Investors rebalance to other sectors. Gilead Sciences (GILD) up over 6% and. boosts overall market with positive remdesivir data. NAZ up 2.84%, IBB up 1.3%, IJR break-out? Technology, financials and energy show...
by Raynovich Rod | Apr 4, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Coronavirus (COVID-19) is an infectious disease currently spreading across the globe. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover. Others (particularly elderly people and those with underlying medical...
by Raynovich Rod | Mar 8, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
3/30 11;30a Major news on COVID-19 diagnostics spark rally. Abbott launches 5 minute test. ABT up 7.28% ,JNJ up 6.8%, all large caps up, IBB up 2.55, XBI up 1.61%. Risk reward still looks good for biotech by year-end 2020. See IBB 2 yr chart below. ======== 3/27 After...
by Raynovich Rod | Mar 2, 2020 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Feb 22, 2020 | Biopharmaceuticals, Macro
2/28 10:15a XBI down to $86 level. Looking today to see what to buy. Bought VCYT yesterday at $23+ GNMK up 39% to $5 handle. Diagnostic and tools sector could be the place to look for buys but stocks are extremely volatile—-but now one hour later up only 20%!!...
by Raynovich Rod | Feb 13, 2020 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 Mid-day trading 2/21 NAZ down 1.14%-Biotech stocks held their levels on a down day. Most large cap Raygent focus stocks are in green: ABBV,BMY,GILD up 4%, RHHBY. Mid-caps are mixed but BMRN is up 5%. Healthcare sector was a leader up 0.1% ============...
by Raynovich Rod | Feb 11, 2020 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Companies – Q1 2020 Update The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy ’15. FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected. Our Top...
by Raynovich Rod | Feb 6, 2020 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 2/10…Rally has expanded to mid-caps:ALNY ACAD GWPH ICPT SRPT Etc. ======= Update-1 2/7. 2p …Abbvie (ABBV) Another one of our top large cap picks ABBV is up 6% o the $92 handle as of mid-day trading on earnings and Allergan acquisition. Full year...
